[{"address1": "275 Wyman Street", "address2": "3rd Floor", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "617 945 5576", "website": "https://www.cogentbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 205, "companyOfficers": [{"maxAge": 1, "name": "Mr. Andrew R. Robbins M.B.A.", "age": 48, "title": "President, CEO & Director", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 1183280, "exercisedValue": 0, "unexercisedValue": 899728}, {"maxAge": 1, "name": "Mr. John L. Green C.A., CPA", "age": 44, "title": "CFO & Principal Accounting Officer", "yearBorn": 1980, "fiscalYear": 2024, "totalPay": 729237, "exercisedValue": 0, "unexercisedValue": 421575}, {"maxAge": 1, "name": "Dr. John Edward Robinson Ph.D.", "age": 50, "title": "Chief Scientific Officer", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 788901, "exercisedValue": 0, "unexercisedValue": 254396}, {"maxAge": 1, "name": "Dr. Jessica  Sachs M.D.", "age": 49, "title": "Chief Medical Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 814184, "exercisedValue": 0, "unexercisedValue": 864159}, {"maxAge": 1, "name": "Mr. Cole  Pinnow", "age": 49, "title": "Chief Commercial Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 443154, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brad  Barnett", "title": "Chief Technology Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Christi  Waarich", "title": "Senior Director of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Evan D. Kearns J.D.", "age": 45, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1979, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Erin  Schellhammer", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Dana R. Martin Pharm.D.", "title": "Senior VP of Medical Affairs & Chief Patient Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 9, "overallRisk": 7, "governanceEpochDate": 1756684800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 12.72, "open": 12.75, "dayLow": 11.95, "dayHigh": 12.75, "regularMarketPreviousClose": 12.72, "regularMarketOpen": 12.75, "regularMarketDayLow": 11.95, "regularMarketDayHigh": 12.75, "payoutRatio": 0.0, "beta": 0.35, "forwardPE": -5.204348, "volume": 4749212, "regularMarketVolume": 4749212, "averageVolume": 2756465, "averageVolume10days": 2244300, "averageDailyVolume10Day": 2244300, "bid": 9.06, "ask": 12.01, "bidSize": 2, "askSize": 21, "marketCap": 1672218624, "fiftyTwoWeekLow": 3.72, "fiftyTwoWeekHigh": 13.5, "fiftyDayAverage": 12.0201, "twoHundredDayAverage": 8.27435, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1603832704, "profitMargins": 0.0, "floatShares": 102748660, "sharesOutstanding": 139700796, "sharesShort": 13067172, "sharesShortPriorMonth": 12618086, "sharesShortPreviousMonthDate": 1753920000, "dateShortInterest": 1756425600, "sharesPercentSharesOut": 0.0935, "heldPercentInsiders": 0.00035999998, "heldPercentInstitutions": 1.05601, "shortRatio": 10.0, "shortPercentOfFloat": 0.1062, "impliedSharesOutstanding": 142515008, "bookValue": 0.413, "priceToBook": 28.983053, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -284076000, "trailingEps": -2.08, "forwardEps": -2.3, "lastSplitFactor": "1:4", "lastSplitDate": 1604880000, "enterpriseToEbitda": -5.398, "52WeekChange": 0.12394369, "SandP52WeekChange": 0.1653893, "quoteType": "EQUITY", "currentPrice": 11.97, "targetHighPrice": 30.0, "targetLowPrice": 11.0, "targetMeanPrice": 21.09091, "targetMedianPrice": 20.0, "recommendationMean": 1.83333, "recommendationKey": "buy", "numberOfAnalystOpinions": 11, "totalCash": 237848000, "totalCashPerShare": 1.702, "ebitda": -297123008, "totalDebt": 60658000, "quickRatio": 4.071, "currentRatio": 4.194, "debtToEquity": 39.125, "returnOnAssets": -0.53150004, "returnOnEquity": -1.07552, "freeCashflow": -126128624, "operatingCashflow": -233614000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "COGT", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Cogent Biosciences, Inc.", "marketState": "CLOSED", "earningsTimestamp": 1754397000, "earningsTimestampStart": 1754397000, "earningsTimestampEnd": 1754397000, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -2.08, "epsForward": -2.3, "epsCurrentYear": -2.17765, "priceEpsCurrentYear": -5.4967513, "fiftyDayAverageChange": -0.050099373, "fiftyDayAverageChangePercent": -0.0041679665, "twoHundredDayAverageChange": 3.69565, "twoHundredDayAverageChangePercent": 0.44663933, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Unum Therapeutics Inc.", "nameChangeDate": "2025-09-19", "averageAnalystRating": "1.8 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1522330200000, "postMarketChangePercent": -1.27068, "postMarketPrice": 11.8179, "postMarketChange": -0.152101, "regularMarketChange": -0.75, "corporateActions": [], "postMarketTime": 1758317581, "regularMarketTime": 1758312000, "exchange": "NMS", "messageBoardId": "finmb_675599465", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -5.89623, "regularMarketPrice": 11.97, "regularMarketDayRange": "11.95 - 12.75", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 2756465, "fiftyTwoWeekLowChange": 8.25, "fiftyTwoWeekLowChangePercent": 2.217742, "fiftyTwoWeekRange": "3.72 - 13.5", "fiftyTwoWeekHighChange": -1.5299997, "fiftyTwoWeekHighChangePercent": -0.113333315, "fiftyTwoWeekChangePercent": 12.394369, "dividendDate": 1604880000, "shortName": "Cogent Biosciences, Inc.", "displayName": "Cogent Biosciences", "trailingPegRatio": null, "__fetch_time": "2025-09-20"}]